** Medical equipment maker Penumbra PEN.N rise 8.39% to $293.90 in premarket trading
** Revenue rises 10.8% to $315.52 million from a year earlier in fourth quarter; analysts expected $311.52 million, per data compiled by LSEG
** "We expect cash generation to scale nicely in the coming years," analysts at Morgan Stanley say
** J.P.Morgan says "with another year of low-to-mid teens sales growth on tap plus nice margin expansion Penumbra is delivering good fundamental results"
** Of the 19 brokerages covering the stock, at least 14 raised their price targets following the results
** Brokerage Canaccord Genuity raises PT to $340, a Wall Street high, from $323
** Average rating is "buy", with a median PT of $308 - LSEG
** As of last close, stock up ~14% this year; stock fell ~6% in 2024
(Reporting by Joel Jose in Bengaluru)
((joeljose@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。